TomTec Imaging Systems, a Munich-based company specializing in medical imaging and information management software with a focus on ultrasound technologies, has just announced its groundbreaking 4D RV-Function© software that allows extensive assessment of the right ventricle (RV) of the heart. This diagnostic and disease monitoring tool can prove to be critical in evaluating compensatory ventricular hypertrophy, which can be caused by pulmonary hypertension. 4D RV-Function provides a fast and reproducible examination of the RV, which boosts diagnostic confidence by allowing an accurate 3D visualization.
Pulmonary hypertension is a chronic, life-threatening cardiopulmonary affectation that causes inefficient blood flow into the lungs, resulting in inadequate oxygenation and blood backflow into the right ventricle. A common complication of PH is right-side congestive heart failure. The best way for PH patients to prolong survival without reducing quality of life is to get an early and accurate diagnosis, and to start treatment immediately.
This novel software enables the user to study the right ventricle’s visual geometry, volume, and strain, providing input on EDV, ESV, RVEF, SV, RVLS, TAPSE and FAC, as well as distance measurements. Clinically, it enables real-time and automatic contour proposals, right ventricle longitudinal strain for septum and free wall, and saves users time by allowing them to store their acquisition windows along with bookmarks for future follow-up appointments.
“With our innovative 4D RV-Function software you can visualize the true RV geometry! Our 4D RV-Function will save you time and money by combining our long-lasting experience with the right ventricle 3D model and an easy, user-friendly 4 step workflow,” said Gregor Malischnig, Chief Marketing Officer at TomTec Imaging Systems.
4D RV-Function was developed in collaboration with some of the world’s most accomplished cardiologists and pediatricians, making it a potential forerunner in conducting comprehensive examinations of diseases that affect the RV such as, pulmonary hypertension, congestive heart failure, congenital heart disease, and hypoplastic right heart. The company is set to officially launch the product in Europe in January 2015.